Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
      Description

      Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available.

      Conditions
      Thyroid CancerSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)HRAS Mutant TumorOther Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor
      Talk to us